Oct. 06, 2025 1:29 PM ETTEVA, ABBV, JNJ, NVS, RHHBY, TAK, REGN, MRK, RDY, SDZNY, AMGN, SNY, INCY, LLY, GILD, LEGN, BMY, PFE, GSK, AZN, KMDA, CSLLY, GRFS, RHHBF, RHHVF, ROCH:CA, ROG:CA, SAN:CA, AZNCF, SDZXF, SNYNF, ABBV:CA, TEVJF, TKPHF, BMYMP, CELG.RT, NVSEF, NVS:CA, CMXHF, MRK:CA, LLY:CA, GIFLF, JNJ:CA, GIFOF, GIKLY, GLAXF, GILD:CA, IBB, XBI, SPY, BIIB, VTRS, ARKG, PFE:CA, ALVO, PHAT, ALVOW1 CommentALLKA Research2.85K FollowersWhile AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic.And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone.Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.Gastroenterology, oncology, autoimmune, and rare diseases are, in my opinion, the most interesting therapeutic areas in terms of commercial prospects.By opening this article, you'll discover an in-depth analysis of 5 companies that may be of interest to Big Pharma players.Deagreez/iStock via Getty ImagesOn September 17, the Fed began cutting interest rates again, which historically preceded Big Pharma's increased activity in the M&A space.Since I previously published my approach to selecting pharma stocks in the articles "TopThis article was written byALLKA Research2.85K FollowersWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Research thrives on simplifying investment strategies, ensuring accessibility for both seasoned investors and those just starting.Driven by an unwavering passion for empowering others financially, Allka Research seeks to share its wealth of knowledge through Seeking Alpha. Its mission is to contribute thought-provoking analyses and informed perspectives to the Seeking Alpha community. With a desire to demystify the intricacies of investing, Allka Research aims to inspire confidence in its readers, fostering a community of informed investors who can navigate the markets with intelligence and understanding. Join Allka Research on this exciting journey of discovery and wealth creation as it continues to unravel the secrets of the financial world on Seeking Alpha.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ALVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comment(1)Recommended For You